

Indiana Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Indiana from January 2017 through December 2017.

Key Indiana Findings



Rejection Rate:

24%



Appeals Rate:

29%



Final Rejections:

1,708

Of health plans that received at least 150 claims for PCSK9 inhibitors, the following had the **highest rates of rejections**:

- Anthem **58%**
- MDwise **37%**
- Express Scripts **42%**
- CVS Health **25%**

The following had the **lowest rates of rejection**:

- Aetna **10%**
- Humana Health Plan **9%**



The following table details claims data for the Indiana managed care organizations that received at least 150 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
Anthem	58%	366	212
Express Scripts	42%	517	217
MDwise	37%	153	56
CVS Health	25%	772	195
United Health Group	23%	1,179	269
Cigna Healthcare	18%	314	57
UAW Retiree Medical Benefits Trust	12%	199	24
Aetna	10%	619	63
Humana Health Plan	9%	1,623	154

Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

